NYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free PRME Stock Alerts $4.84 +0.41 (+9.26%) (As of 10:11 AM ET) Add Compare Share Share Today's Range$4.65▼$4.9150-Day Range$4.30▼$9.3952-Week Range$4.11▼$17.20Volume165,054 shsAverage Volume678,175 shsMarket Capitalization$580.90 millionP/E RatioN/ADividend YieldN/APrice Target$16.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Prime Medicine alerts: Email Address Prime Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside281.2% Upside$16.89 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 15 Articles This WeekInsider TradingAcquiring Shares$20 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.80) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 starsMedical Sector400th out of 915 stocksBiological Products, Except Diagnostic Industry58th out of 153 stocks 3.4 Analyst's Opinion Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoveragePrime Medicine has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRME. Previous Next 0.0 Dividend Strength Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRME. Previous Next 1.8 News and Social Media Coverage News SentimentPrime Medicine has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Prime Medicine this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.29% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.80) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Prime Medicine Stock (NYSE:PRME)Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Read More PRME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRME Stock News HeadlinesApril 29, 2024 | marketwatch.comPrime Medicine Gets FDA Clearance for PM359 IND ApplicationApril 29, 2024 | markets.businessinsider.comPrime Medicine Announces FDA Clearance Of IND Application For Pm359 - Quick FactsApril 29, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 29, 2024 | globenewswire.comPrime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)April 27, 2024 | americanbankingnews.comPrime Medicine (NYSE:PRME) Reaches New 1-Year Low at $4.32April 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical OutlookApril 24, 2024 | americanbankingnews.comPrime Medicine's (PRME) Outperform Rating Reaffirmed at WedbushApril 23, 2024 | globenewswire.comPrime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsApril 29, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! April 23, 2024 | americanbankingnews.comPrime Medicine (NYSE:PRME) Now Covered by Chardan CapitalApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic ProgressApril 22, 2024 | nasdaq.comChardan Capital Initiates Coverage of Prime Medicine (PRME) with Buy RecommendationApril 10, 2024 | uk.investing.comTD Cowen initiates Prime Medicine stock with Buy on editing platformMarch 27, 2024 | fool.com2 Magnificent Growth Stocks With Room to RunMarch 15, 2024 | cnet.com13 Best Little-Known Perks You Can Get From Amazon PrimeMarch 14, 2024 | msn.comGeron wins FDA AdCom backing for blood cancer drugMarch 14, 2024 | investorplace.comShort-Squeeze Roulette: 3 Stocks That Could Leave Bears BeggingMarch 12, 2024 | markets.businessinsider.comBuy Rating Justified: Prime Medicine’s Promising Clinical Prospects and Innovative Gene Editing Technology Poised for GrowthMarch 12, 2024 | msn.comBlinken to travel to Jamaica for CARICOM meeting on Haiti, US State Dept saysMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Anticipated IND Filing and Strong Gene Editing PipelineMarch 1, 2024 | investorplace.comCathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?March 1, 2024 | benzinga.comRecap: Prime Medicine Q4 EarningsMarch 1, 2024 | msn.comPrime Medicine GAAP EPS of -$2.18March 1, 2024 | globenewswire.comPrime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesFebruary 29, 2024 | benzinga.comThomas Cahill's Net WorthFebruary 28, 2024 | globenewswire.comPrime Medicine to Participate in Upcoming Investor ConferencesFebruary 27, 2024 | 247wallst.comStock Offerings Prompt Big Insider BuyingSee More Headlines Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2024Today4/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PRME CUSIPN/A CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Target$16.89 High Stock Price Target$26.00 Low Stock Price Target$9.00 Potential Upside/Downside+281.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.30% Return on Assets-71.65% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book3.23Miscellaneous Outstanding Shares120,020,000Free Float90,868,000Market Cap$531.69 million OptionableOptionable Beta1.81 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Keith Michael Gottesdiener Ph.D. (Age 70)President, CEO, Secretary & Director Comp: $924.04kDr. Ann L. Lee Ph.D. (Age 62)Chief Technical Officer Comp: $947.28kMr. Richard Brudnick (Age 66)Chief Business Officer Comp: $680.8kDr. Andrew Anzalone M.D. (Age 37)Ph.D., Co-Founder & Head of Prime Editing Platform Dr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Allan Reine M.D. (Age 49)Chief Financial Officer Dr. Meredith Goldwasser (Age 52)Senior VP and Head of Strategy & Corporate Operations Ms. Carman Alenson CPA (Age 58)M.B.A., Senior VP of Finance & Chief Accounting Officer Dr. Jeremy S. Duffield M.D. (Age 56)Ph.D., Chief Scientific Officer Comp: $994.4kDr. Karen Brown J.D.Ph.D., Senior Vice President of Intellectual Property & Legal AffairsMore ExecutivesKey CompetitorsVectivBioNASDAQ:VECTAllogene TherapeuticsNASDAQ:ALLONovavaxNASDAQ:NVAXValnevaNASDAQ:VALNFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 154,366 shares on 4/19/2024Ownership: 2.805%TrueMark Investments LLCBought 10,153 shares on 4/15/2024Ownership: 0.071%Green Alpha Advisors LLCBought 4,200 shares on 4/10/2024Ownership: 0.028%Chelsea Counsel Co.Bought 4,400 shares on 2/21/2024Ownership: 0.005%Robert NelsenBought 3,200,000 shares on 2/15/2024Total: $20 M ($6.25/share)View All Insider TransactionsView All Institutional Transactions PRME Stock Analysis - Frequently Asked Questions Should I buy or sell Prime Medicine stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRME shares. View PRME analyst ratings or view top-rated stocks. What is Prime Medicine's stock price target for 2024? 10 analysts have issued 1-year price targets for Prime Medicine's shares. Their PRME share price targets range from $9.00 to $26.00. On average, they predict the company's stock price to reach $16.89 in the next twelve months. This suggests a possible upside of 281.2% from the stock's current price. View analysts price targets for PRME or view top-rated stocks among Wall Street analysts. How have PRME shares performed in 2024? Prime Medicine's stock was trading at $8.86 at the start of the year. Since then, PRME shares have decreased by 50.0% and is now trading at $4.43. View the best growth stocks for 2024 here. When is Prime Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRME earnings forecast. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) released its earnings results on Friday, March, 1st. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. What ETFs hold Prime Medicine's stock? ETFs with the largest weight of Prime Medicine (NYSE:PRME) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK). When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an IPO on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Prime Medicine's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.81%), TrueMark Investments LLC (0.07%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2019 Gp LLC Gv and Robert Nelsen. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PRME) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
